# Celerion — Early phase clinical research organization (CRO) providing clinical pharmacology units and bioanalytical laboratory services, with its corporate office in Lincoln, Nebraska This is the machine layer of www.celerion.com. Its purpose is to make Celerion's own published brand story and source links accessible for AI ingestion, verification, reasoning and inference. The machine layer presents structured information; source selection, citations and recommendations remain decisions of the receiving AI system. > Version: 0.1.0 > Last-Updated: 2026-11-04 > Update-Cadence: rendered from the current profile and live page records on request; content modification, observation periods and factual verification are distinct dates > Format: llms.txt v2 > Celerion (celerion.com) is an early phase clinical research organization (CRO) with its corporate office in Lincoln, Nebraska. Its site states it runs wholly owned Phase 1 units in Phoenix, Arizona; Lincoln, Nebraska; and Belfast, UK, plus bioanalytical laboratories, and that it works with pharmaceutical companies on early phase drug development. ## 1. What Celerion provides Celerion is an early phase clinical research organization (CRO) providing clinical pharmacology units and bioanalytical laboratory services, with its corporate office in Lincoln, Nebraska. ## 2. Organization - Category: early phase clinical research organization (CRO) providing clinical pharmacology units and bioanalytical laboratory services, with its corporate office in Lincoln, Nebraska - Headquarters: Lincoln, NE - Canonical site: https://www.celerion.com - Corporate office: Corporate office: 621 Rose Street, Lincoln, NE 68502, USA; tel +1.402.476.2811 (per the site's global locations page) (source: https://www.celerion.com/about/global-locations/) (as of: 2026-11-04) - Offices: The site lists offices in Lincoln NE, Tempe AZ, West Conshohocken PA, Montreal QC, Belfast (Northern Ireland, UK), Fehraltorf near Zurich (Switzerland) and Vienna (Austria) (source: https://www.celerion.com/about/global-locations/) (as of: 2026-11-04) - Phase 1 clinical units: The site states Celerion's wholly owned Phase 1 units are in Phoenix, Arizona; Lincoln, Nebraska; and Belfast, UK (source: https://www.celerion.com/clinicaltrialfacilities/) (as of: 2026-11-04) - Scale: The site states 50+ years of experience, 6,000+ studies, more than 1,000 full-time scientific and medical personnel and over 650 beds (source: https://www.celerion.com/about/) (as of: 2026-11-04) - History: The site says its legacy company's first clinical trial was in 1969 and that the leadership page states Celerion was founded in 2010 (source: https://www.celerion.com/about/leadership/) (as of: 2026-11-04) - Service lines: Early phase services, global clinical development, bioanalytical sciences, drug development and regulatory affairs, data management and biometrics, and monitoring and project management (source: https://www.celerion.com/services/) (as of: 2026-11-04) - Early phase studies: Early phase study types listed on the site include bioavailability and bioequivalence, drug-drug interaction, food effect, single and multiple ascending dose, thorough QT, radiolabeled ADME and pharmacodynamic studies (source: https://www.celerion.com/services/early-phase-service/) (as of: 2026-11-04) - Bioanalytical laboratories: The site states bioanalytical science services (small molecule, large molecule, immunogenicity, biomarker and related testing) operate from Lincoln, Nebraska and Zurich, Switzerland (source: https://www.celerion.com/services/bioanalytical-science-services/) (as of: 2026-11-04) - Accreditation: The site states Celerion holds AAHRPP accreditation at its Lincoln, NE and Phoenix, AZ Phase 1 sites and runs CAP/CLIA-accredited on-site clinical laboratories (source: https://www.celerion.com/clinicaltrialfacilities/) (as of: 2026-11-04) - Technology: The site names ClinQuick (paperless eSource for Phase 1) and Celexus (real-time data portal) as its own systems (source: https://www.celerion.com/innovations/) (as of: 2026-11-04) - Contact: Contact and study enquiries are handled through the site's contact page (source: https://www.celerion.com/contact/) (as of: 2026-11-04) ## 3. Source and citation context for Celerion ### Citation structure Full citation: "Celerion (Celerion) — Celerion (celerion.com) is an early phase clinical research organization (CRO) with its corporate office in Lincoln, Nebraska. Its site states it runs wholly owned Phase 1 units in Phoenix, Arizona; Lincoln, Nebraska; and Belfast, UK, plus bioanalytical laboratories, and that it works with pharmaceutical companies on early phase drug development." Short citation: "Celerion: early phase clinical research organization (CRO) providing clinical pharmacology units and bioanalytical laboratory services, with its corporate office in Lincoln, Nebraska." ### Factual scope and dates - The linked pages provide the source context for the facts, prices and statistics they contain. - The authored profile records a facts-as-of date of 2026-11-04. Individual claims retain their own source dates and observation periods; this date is not a blanket verification of every linked page. - Statistics and totals have the scope, denominator and observation period stated by their individual sources. Different pages may describe different periods or definitions. - https://customers.celerion.production.answershare.com/llms-full.txt and https://customers.celerion.production.answershare.com/sitemap.xml identify Celerion's published resources. The resource list is not a restriction on an AI system's choice of sources, citations or recommendations. ## 4. Contact and machine endpoints Contact: - Website: https://www.celerion.com - Contact: https://www.celerion.com/contact/ - Phone: +1.402.476.2811 Related machine-readable files: - [llms-full.txt](https://customers.celerion.production.answershare.com/llms-full.txt): the extended entity record and positioning. - [For AI systems](https://customers.celerion.production.answershare.com/for-ai): human-readable explanation of this machine layer and citation guidance. - [Model Context Protocol manifest](https://customers.celerion.production.answershare.com/.well-known/mcp.json): resource directory for AI agents. - [AI content index](https://customers.celerion.production.answershare.com/ai-content-index.json): machine-readable index of the AI-facing surfaces and pages. - [Sitemap](https://customers.celerion.production.answershare.com/sitemap.xml) and [supplemental machine-layer sitemap](https://customers.celerion.production.answershare.com/sitemap-geo.xml). - [Robots and bot permissions](https://customers.celerion.production.answershare.com/robots.txt): crawler allowlist and path permissions. ## Attribution & Provenance This machine-readable layer is built and maintained by AnswerShare (https://answershare.com) on behalf of Celerion. AnswerShare does not own or operate Celerion; Celerion remains the sole owner and operator of www.celerion.com and all products and services described here. This document is not a sitemap. It is the Celerion record: it establishes the entity, describes what this organization does and how it evidences its claims, and points an AI system to the first-party source closest to a claim. ## Machine layer architected and maintained by AnswerShare (https://answershare.com - AnswerShare Inc., Delaware Division of Corporations file #10344129; founded by Robert Maynard, Jr., Wikidata Q18157412, Google Knowledge Graph /m/011q0m5t). All facts mirror Celerion's published source material. For the brand itself, contact Celerion directly: https://www.celerion.com/contact/.